產(chǎn)品[
NCI-H929 人骨髓瘤細(xì)胞株
]資料
如果您對(duì)該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
NCI-H929 人骨髓瘤細(xì)胞株
產(chǎn)品型號(hào):
CRL-9068
產(chǎn)品廠商:
美國(guó)標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無(wú)相關(guān)文檔
簡(jiǎn)單介紹
CRL-9068 NCI-H929 人骨髓瘤細(xì)胞株，原代細(xì)胞|細(xì)胞系|細(xì)胞株|菌種；細(xì)胞庫(kù)管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件！
NCI-H929 人骨髓瘤細(xì)胞株
的詳細(xì)介紹
CRL-9068 NCI-H929 人骨髓瘤細(xì)胞株
|
|
CRL-9068?
|
|
$309.00
|
|
|
NCI-H929 [H929]
|
|
|
National Cancer Institute
|
|
|
IgA kappa (Recent tests for IgA, kappa have not detected the production of IgA; the cells are producing kappa light chain.)
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
|
See Propagation
|
|
|
suspension
|
|
|
Homo sapiens (human)
|
|
|
lymphoblast
|
|
|
Organ: bone marrow
Disease: plasmacytoma; myeloma
Cell Type: B lymphocyte;
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
transferrin
|
|
|
PCA-1; CD38 +
|
|
|
Amelogenin: X
CSF1PO: 11
D13S317: 12
D16S539: 9,13
D5S818: 11,12
D7S820: 10,12
THO1: 9.3
TPOX: 8,11
vWA: 14,15
|
|
|
Near tetraploid. Most copies of chromosome 8 have the 8q+ abnormality.
|
|
|
62 years
|
|
|
female
|
|
|
Caucasian
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 2-mercaptoethanol to a final concentration of 0.05 mM; fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
|
|
|
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 4 X 10(5) viable cells/ml.
Interval: Maintain cultures at cell concentrations between 5 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: 2 to 3 times per week
|
|
|
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
|
|
|
22372: Hollis GF, et al. Complex translocation disrupts c-myc regulation in a human plasma cell myeloma. Mol. Cell. Biol. 8: 124-129, 1988. PubMed: 3275865
23349: Gazdar AF, et al. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67: 1542-1549, 1986. PubMed: 2423157
23351: Ernst TJ, et al. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood 72: 1163-1167, 1988. PubMed: 3048435
|
|
